Developing a Natural History Model for Duchenne Muscular Dystrophy.

Broomfield, Jonathan; Hill, M; Chandler, F; Crowther, M J; Godfrey, J; Guglieri, M; Hastie, J; Larkindale, J; Mumby-Croft, J; Reuben, E; Woodcock, F; Abrams, K R

Broomfield, Jonathan; Hill, M; Chandler, F; Crowther, M J; Godfrey, J; Guglieri, M; Hastie, J; Larkindale, J; Mumby-Croft, J; Reuben, E; Woodcock, F; Abrams, K R.

Afiliación

Broomfield J; University of Leicester, Leicester, UK. jb781@leicester.ac.uk.
Hill M; GlaxoSmithKline, Middlesex, UK.
Chandler F; Sanofi, Reading, UK.
Crowther MJ; Duchenne UK, London, UK.
Godfrey J; Karolinska Institute, Stockholm, Sweden.
Guglieri M; Red Door Analytics, Stockholm, Sweden.
Hastie J; JG Zebra Consulting, London, UK.
Larkindale J; Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.
Mumby-Croft J; Sanofi, Reading, UK.
Reuben E; Critical Path Institute, Tucson, USA.
Woodcock F; Source Health Economics, Oxford, UK.
Abrams KR; Duchenne UK, London, UK.

Pharmacoecon Open ; 8(1): 79-89, 2024 Jan.

Article en En | MEDLINE | ID: mdl-38019449

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmacoecon Open Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google